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Abstract
Background: NH exchangers (NHEs) play a crucial role in regulating intra/extracellular pH, which is altered in
cancer cells, and are therefore suitable targets to alter cancer cell metabolism in order to inhibit cell survival and
proliferation. Among NHE inhibitors, amiloride family members are commonly used in clinical practice as diuretics;
we focused on the amiloride HMA, reporting a net cytotoxic effect on a panel of human cancer cell lines; now we
aim to provide new insights into the molecular events leading to cell death by HMA.
Methods: Colon cancer cell lines were treated with HMA and analysed with: morphological and cellular assays
for cell viability and death, and autophagy; biochemical approaches to evaluate mitochondrial function and ROS
production; in situ detection of DNA damage; molecular tools to silence crucial autophagy/necroptosis factors.
Results: HMA affects cellular morphology, alters mitochondrial structure and function, causes an increase in ROS,
which is detrimental to DNA integrity, stimulates poly(ADP-ribose) synthesis, activates RIPK3-dependent death
and triggers autophagy, which is unable to rescue cell survival. These features are hot points of an intricate
network of processes, including necroptosis and autophagy, regulating the homeostasis between survival and death.
Conclusion: Our results allow the identification of multiple events leading to cell death in cancer cells treated
with HMA. The here-defined intricate network activated by HMA could be instrumental to selectively target the
key players of each pathway in the attempt to improve the global response to HMA. Our data could be the
starting point for developing a newly designed targeted therapy.
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Background
Cancer cells have to reassess their own metabolism in
order to sustain high proliferation rate requiring a con-
tinuous need of ATP; also the tumour microenviron-
ment, which is characterised by peculiar features
including hypoxia and acidosis, favours cancer cell pro-
liferation [1]. Malignant cells counteract the persistent
oxygen demand by turning the high glycolysis rate into
anaerobic lactic acid fermentation (“Warburg effect”,
from Otto Heinrich Warburg who first hypothesised
this phenomenon [2]). Acidosis is managed through the
exchanges between the tumour cell and microenviron-
ment [3, 4], governed by membrane bound proton
pumps/transporters and Na+/H+ exchangers (NHEs) [5].
The best characterised NHEs regulate the intracellular pH
through the exchange of intracellular H+ with extracellular
Na+, and, in turn, cause the alkalinisation of the cytosol
that sustains cancer growth; being hyperactivated in can-
cer cells, they became potent targets having an impact on
tumour development, growth and spread [5, 6].
Several NHE inhibitors were developed (e.g. 2-
aminophenoxazine-3-one, compound 9 T, cariporide and
amiloride) [3, 4]. We focused on the amiloride derivative
HMA (5-(N,N-hexamethylene) amiloride), showing a pe-
culiar physical feature, which is to be fluorescent under
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conventional UV excitation in an acid milieu [7]. We de-
tected an intense cytoplasmic blue fluorescent signal in
human Adult Retinal Pigmented Epithelium 19 (ARPE19)
cells incubated for short times with HMA, followed by im-
paired cell survival [7, 8].
The interest toward HMA is legitimated by the evi-
dence that it is poorly toxic to non-transformed breast
cells and mouse mammary cells compared to trans-
formed breast cancer cell lines and mouse mammary
cancer cells, suggesting that HMA targets selectively
cancer cells [9]. As for identifying the death pathways
responsible for HMA cytotoxic effect, we and others
[9, 10] previously reported that HMA affects cell sur-
vival by triggering caspase-independent paradigms of
cell death in human cancer cell lines [9, 10], as it oc-
curred also for other amiloride derivatives [11, 12]. In
the present study, we characterised the molecular
events regulating HMA cytotoxicity in colon cancer
cells, reporting alterations in mitochondrial structure
and function triggering ROS (reactive oxygen species)
production, DNA damage and poly(ADP-ribose) syn-
thesis. Finally, we investigated the possible involvement




Colon carcinoma HCT-116 cells (from Dr. C.R. Boland
[13]) were cultured in D-MEM supplemented with 10 %
foetal calf serum (FCS), 4 mM glutamine, 2 mM Na
pyruvate, 100 U/ml penicillin and 0.1 mg/ml strepto-
mycin. Colon adenocarcinoma HT-29 cells (obtained
from Dr. R. Supino [14]) were grown in McCoy medium
supplemented as for D-MEM. Reagents were purchased
from Thermo Fisher (Waltham, MA, USA) and Euroclone
(Milano, Italy). Cells were grown as monolayer at 37 °C in
humidified atmosphere containing 5 % CO2 in 75 cm
2
flasks (Corning, Amsterdam, The Netherlands). At
confluence, cells were trypsinised with trypsin-EDTA
(stock solution 10X, Sigma-Aldrich, Saint Louis, MO,
USA) diluted in PBS (Thermo Fisher).
Cell treatments
Cell lines were treated with HMA (Sigma-Aldrich,
stock solution 80 mM in DMSO) at concentrations ran-
ging from 5 μM to 40 μM (accordingly to [10]) for the
time periods indicated in the text. In some experiments,
cells were treated with 15 mM NAC (N-acetyl cysteine,
Sigma-Aldrich, stock solution 100 mM); 20 μM
zVAD.fmk (Bachem, Heidelberg, Germany, stock solu-
tion 20 mM); 50 μM Necrostatin-1 (Biomol, Hamburg,
Germany, stock solution 38.56 mM); 10 μM Olaparib
(SelleckChem, Houston, TX, USA, stock solution
100 mM); 400 μM α-Tocopherol (Sigma-Aldrich, stock
solution 22.36 mM). Parallel samples were incubated
with 0.1 % DMSO, i.e. the same final concentration
used with the highest drug concentration.
Morphological analysis
Cells (either unfixed or being fixed with 4 % paraformal-
dehyde (PFA) in PBS) were analysed in bright field
microscopy.
Transmission electron microscopy
For transmission electron microscopy (TEM), cells were
processed as follows. Some cells were fixed with 2.5 %
(v/v) glutaraldehyde and 2 % (v/v) PFA in 0.1 M phos-
phate buffer; pH 7.4, at 4 °C for 1 h, washed and incu-
bated with 3,3’ diaminobenzidine (DAB, Sigma-Aldrich)
(2 mg/ml in 50 mM Tris-HCl; pH 7.6) under simultan-
eous irradiation with two 8 W Osram Blacklite 350
lamps for 2 h at room temperature (spectral emission
range between 430 and 470 nm, thus being suitable for
FITC excitation). The cells were then post-fixed with
1 % osmium tetroxide (Electron Microscopy Sciences,
Hatfield, PA, USA) and 1.5 % potassium ferrocyanide
(Sigma-Aldrich) at room temperature for 1 h, dehy-
drated with acetone and embedded in Epon (Agar Scien-
tific, Assing, Monterotondo, Italy). Parallel samples, after
aldehyde fixation, were incubated with DAB under light
irradiation, dehydrated with ethanol and embedded in
LR White resin. As negative controls, some samples
were processed as described above but omitting both
DAB incubation and exposure to the excitation light. Ul-
trathin sections were weakly stained with uranyl acetate
(Agar Scientific). The samples were finally examined and
photographed with a Zeiss EM 900 electron microscope
at 80 KV (Carl Zeiss, Jena, Germany). The micrographs
were then developed and digitalised [15].
Cell death analysis
Cells were seeded at the density of 2x104/well in 24-well
plates. After 24 h, cells were treated with the selected
drug. At the end of the treatment, the cells were rinsed
with PBS and trypsinised, washed in binding buffer
(0.1 mM Hepes, 2.5 mM CaCl2, 140 mM NaCl; pH 7.4)
and incubated for 15 min with Annexin V-FITC (Milteny
Biotech, Bergisch Gladbach, Germany, 3 % in binding
buffer). Samples were then washed again in binding
buffer, stained with PI (propidium iodide, Sigma-
Aldrich, diluted 1:1000 in binding buffer) and imme-
diately analysed by flow cytometry (FACSCanto II, BD
Biosciences, Heidelberg, Germany).
Western blot
The expression level of a panel of proteins in total ex-
tracts was analysed by Western blot according to proce-
dures routinely used in the laboratory [10, 16] using the
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primary antibodies listed in Table 1. HRP conjugated
secondary antibodies were from Jackson Immuno-
Research (Suffolk, UK). Three independent experiments
were carried out. Band quantification was performed
using ImageJ software (https://imagej.nih.gov/ij/).
Indirect immunofluorescence
Cells were seeded on coverslips (16-mm diameter) in
12-well plates, at the density of 5x104 cells/ml. After
24 h, cells were treated with the appropriate drug con-
centration for increasing times (up to 24 h). The follow-
ing antigens were probed:
p62: cells were fixed in PFA (2 % in PBS) for 15 min
on ice, kept overnight in 70 % ethanol at -20 °C,
washed three times in PBS, incubated for 30 min with
5 % skim milk in PBS, then incubated in a humidified
chamber with polyclonal antibody against p62
(diluted 1:100 in PBS, Enzo Life Science, Farmingdale,
NY, USA) for 1 h at 37 °C, washed three times
with PBS and incubated with secondary antibody
(111-225-003, Cy2-conjugated anti-rabbit, Jackson
Immuno-Research) diluted 1:50 in PBS, for 1 h at 37 °C.
Coverslips were finally washed three times with PBS in
the dark, incubated for 10 min with 0.2 μg/μl DAPI
(Sigma-Aldrich) and washed again for 30 min in PBS.
Slides were finally mounted with 10 μl of Mowiol.
8-oxoG: cells were fixed overnight in methanol/acetone
1:1 at -20 °C, incubated for 45 min with 2 N HCl in
order to allow access of the antibody to the chromatin,
then neutralised for 25 min with 0.1 mM sodium
tetraborate; pH 8.0. Subsequently, samples were
incubated with 1 % BSA (in PBS containing 0.2 %
Tween-20) for 15 min and stained for 1 h with the
anti-8-oxoG antibody (clone N45.1, JaICA, Shizuoka,
Japan) diluted 1:300 in PBS containing 0.2 % Tween.
Coverslips were then washed and incubated with the
goat anti-mouse secondary antibody (488-labelled
Dylight, KPL, Gaithersburg, MD, USA, diluted
1:100), for 30 min and finally for 30 min with a
donkey anti-goat tertiary antibody (Alexa Fluor 488,
Invitrogen, Molecular Probes) diluted 1:200 in PBS
containing 0.2 % Tween. Coverslips were then
processed as described above.
γ-H2AX: cells were incubated with the monoclonal
antibody against γ-H2AX (JBW301, Merck Millipore,
Milano, Italy; diluted 1:5000 in PBS) according to a
procedure routinely used in our laboratory [17].
GRP78: cells were initially processed as described above
for p62, incubated for 1 h at 37 °C in a humidified
chamber with polyclonal antibody against GRP78
(Thermo Fisher, diluted 1:50 in PBS), washed three
times with PBS and incubated with TRITC-conjugated
anti-mouse secondary antibody (115-025-146; Jackson
Immuno-Research, diluted 1:50 in PBS) for 1 h at 37 °C.
Coverslips were processed as described above.
Ubiquitin: cells were processed as for p62, incubated in
a humidified chamber with the polyclonal antibody
against ubiquitin (diluted 1:100 in PBS [18]) for 1 h at
37 °C, washed three times with PBS and incubated with
the TRITC-conjugated anti-rabbit secondary antibody
(111-025-003, Jackson Immuno-Research, diluted 1:50 in
PBS) for 1 h at 37 °C. Coverslips were processed as above.
LC3, mtHSP70 and poly(ADP-ribose) immunostainings
were performed as previously described [10, 16].
For all the immunofluorescence experiments, cells were
observed using a fluorescence microscope Olympus
BX51, equipped with a 60X objective. The images
were acquired with a digital camera Camedia C4040
(Olympus, Tokyo, Japan); Adobe Photoshop was used
as elaborating software. At least 100 cells per sample
were counted in three independent experiments.
Quantification of ROS
Cells were seeded in 24-well plates at the density of 2x104/
well. After 24 h, cells were treated with the appropriate
drug for the selected time; thereafter, the fluorogenic dye
DCFDA (dichlorofluorescein diacetate, Invitrogen, Molecu-
lar Probes, 10 μg/ml) was added to the medium for 30 min.
After diffusion into the cell, DCFDA is deacetylated by
cellular esterases to a non-fluorescent compound,
which is later oxidized by ROS into 2’,7’-dichlorofluor-
escein (DCF). DCF is a highly fluorescent compound,
which can be detected by fluorescence spectroscopy
with maximum excitation and emission spectra of 495 nm
and 529 nm, respectively. Finally, cells were trypsinised,
resuspended in PBS and analysed by flow cytometry
(FACSCanto II, BD Biosciences). Each experimental point
was conducted in triplicate.
Table 1 Primary antibodies for western blot (diluted 1:1000)
ANTIGEN ANTIBODY SOURCE COMPANY
Atg 7 2631 Rabbit Cell Signaling
Beclin-1 3738 Rabbit Cell Signaling
MLKL GTX107538 Rabbit Acris Antibodies
RIPK1 H207 Rabbit Santa Cruz
RIPK3 IMG-5846A Rabbit Imgenex
α-tubulin DM1A Mouse Sigma-Aldrich
γ-tubulin TU-30 Mouse Santa Cruz
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Evaluation of mitochondrial membrane potential
To determine the mitochondrial membrane potential,
cells were seeded in 24-well plates at the density of
2x104/well, treated with the proper drug and then incu-
bated with 50 nM TMRM (tetramethylrodamine
methylester) (Invitrogen, Molecular Probes) for 10 min
at 37 °C. Thereafter, samples were trypsinised, resus-
pended in 100 μl of PBS and immediately analysed by
flow cytometry (FACSCanto II, BD Biosciences).
RNA interference
For transient knockdown, cells seeded in 24-well plates
(for death analysis) or in 6-well plates (for western blot
analysis) at the density of 7.5x105/well cells were re-
versely transfected with 5 nM Silencer select control
siRNA (4390844) or targeting siRNA (s21741 and
s21741 for RIPK3; s20650, s20651 and s20652 for Atg7;
s16537 and s16538 for Beclin-1), using Lipofectamine
RNAiMAX reagent and Opti-MEM medium according
to manufacturers’ protocols. All reagents were purchased
from Thermo Fisher.
Statistical analysis
The statistical analysis (t-test) was performed using
Excel Office 2011. From the results of three independent
experiments, the average value ± standard deviation
(S.D.) was calculated.
Results
HMA affects cell morphology
A preliminary survey of HMA effects on a panel of hu-
man cancer cell lines proved that HMA exerted a cyto-
toxic effect on three colon cancer cell lines, with an
IC50 value of 22.30 μM for SW613-B3, 23.47 μM for
HCT-116 and 32.19 μM for HT-29 cells [10]. Now, we
aimed at depicting the molecular events leading to
HMA cytotoxicity. First, we exploited the fluorescent
properties of HMA [7] using the diaminobenzidine
(DAB) photo-oxidation technique, which is based on
the formation of an electron-dense osmiophilic product
that precipitates in close proximity to the fluorophore,
thereby allowing its ultrastructural detection [15, 19].
Electron microscopy analysis of HMA-treated HCT-116
colon carcinoma cells revealed electron-dense black
spots within the cytoplasm, enclosed within vesicles
(red*), which are present only as an effect of HMA,
given that in untreated cells no evidence of roundish
deposit of electron-dense products was found (Fig. 1a).
In addition, in HMA-treated samples we detected some
vesicles containing intracellular debris that can be likely
associated to residual cisternae and resemble multilamellar
bodies (red arrowhead) [20]. In fact, vacuole-like structures
and swelling of intracellular structures were detected also
by optical microscopy in the same conditions, exclusively
in HMA-treated cells (Fig. 1b). On the whole, these obser-
vations suggest that HMA induces some mechanical stress
due to the massive presence of vacuoles.
Mitochondrial distribution and function are altered
by HMA
After verifying that HMA had entered the cell and
remained in the cytoplasmic compartment, where it pro-
moted morphological alterations, we addressed its pos-
sible impact on the cytoplasmic organelles that play a
master role in controlling cell metabolism, i.e. mitochon-
dria. Their intracellular distribution was monitored by
indirect immunofluorescence experiments using an anti-
body specific to the mitochondrial chaperone mtHSP70
(red fluorescence). We observed that mitochondria ap-
peared to be rearranged in structure and localisation in
HMA-treated HCT-116 cells: in untreated samples,
mitochondria were distributed throughout the cyto-
plasm, while in HMA-treated cells they were detected as
clustered outside the nuclear membrane (Fig. 1c).
HMA stimulates ROS production
As mitochondrial functions are strictly correlated with
ROS production, we have measured the ROS level
through a cytofluorimetric assay based on the use of the
fluorogenic dye DCFDA that measures hydroxyl, peroxyl
and other ROS within the cell; once diffused into the
cell, it is deacetylated to a non-fluorescent compound,
which is later oxidized by ROS into the highly fluores-
cent compound DCF [21]. In fact, as illustrated in Fig. 2a,
in HMA-treated HCT-116 cells the quantification of
DCF fluorescence intensity, which is proportional to
ROS amount, showed a net time-dependent increase.
When cells were cotreated for increasing times (up to
24 h) with well-known antioxidants, i.e. NAC (N-acetyl-
L-cysteine) and α-Tocopherol (Toc), ROS levels were
drastically reduced (Fig. 2a), indicating that both scaven-
gers were effective in counteracting ROS production
triggered by HMA.
Mitochondrial membrane depolarization
To monitor mitochondrial transmembrane potential, we
used TMRM, a lipophilic cation that normally penetrates
the mitochondrial lipid bilayer and accumulates in the
mitochondrial membrane emitting a fluorescence peak
at 574 nm measurable by flow cytometry while it does
not enter altered mitochondria, thus lowering the de-
tectable intramitochondrial fluorescence. A sharp peak
of fluorescence corresponds to cells with healthy mito-
chondria incorporating and accumulating the dye,
whereas cells presenting depolarized (low fluorescence
emission) or hyperpolarized (high fluorescence emission)
mitochondria can be identified at the left and right side
of the fluorescence peak of untreated cells, respectively.
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For each sample, the number of HCT-116 cells included
in each class was recorded. No high fluorescence emis-
sion/hyperpolarization was observed; the ratio between
cells with low (HMA-treated samples) and normal (un-
treated samples) fluorescence emission was calculated
and reported as fold increase. As shown in Fig. 2b,
HMA induced a net depolarization of the mitochondrial
membrane yet after 4 h of treatment (8.33 folds), which
increased even more at 8 h (11.5 folds) while a pro-
longed incubation allowed the cells to partially buffer
mitochondrial membrane depolarization (8.44 and 6.44
fold at 16 h and 24 h, respectively). Similar results were
obtained with the HT-29 colon cancer cell line (data not
shown). NAC protected the cells from the HMA-
induced depolarization, while no effect was observed
with α-Tocopherol (Fig. 2b). This discrepancy could be
due to the fact that the α-Tocopherol is a lipophilic cat-
ion that enters mitochondrial membranes only if mito-
chondria have an intact membrane potential, while the
mechanism of action of the water-soluble NAC implies a
rapid reaction with highly oxidising radicals.
HMA affects DNA integrity
A high level of ROS is very dangerous for the cell, being a
source of oxidation of DNA and organelles. We monitored
the production of 7,8-dihydro-8-oxoguanine (8-oxoG),
which is the most frequent oxidation product in both
DNA and RNA and possibly contributes to various inflam-
matory processes and aging-related diseases [22]. HCT-
116 cells were analysed by conventional in situ immunola-
beling with a monoclonal antibody against 8-oxoG [23].
As shown in Fig. 2c, untreated cells were negative for the
Fig. 1 HMA affects cell morphology and mitochondria distribution. a TEM (transmission electron microscopy) analysis of diaminobenzidine (DAB)
photo-oxidation in HCT-116 untreated cells and in cells treated with 20 μM HMA for 24 h. Red asterisk marks vesicles enclosing electron-dense
regions within the cytoplasm; red arrowheads refer to vesicles containing intracellular debris. b Bright field microscopy images of HCT-116
cells untreated and treated with 20 μM HMA for 24 h; nuclei are marked with *. c Immunofluorescence analysis of mitochondrial HSP70 in untreated
and HMA-treated (20 μM for 24 h) HCT-116 cells. Scale bar: 50 μm. A representative experiment out of three is shown
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Fig. 2 (See legend on next page.)
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presence of 8-oxoG, while in all the cells treated for 24 h
with 20 μM HMA, brilliant green fluorescent foci corre-
sponding to the formation of 8-oxoG were clearly visible,
confirming the presence of oxidised bases previously ob-
served by the comet assay in HMA-treated cancer cells,
thus supporting the postulated correlation between ROS
production and base oxidation [10]. In parallel samples
treated with NAC in combination with HMA, few foci
were still detectable, possibly due to a low residual ROS
amount (Fig. 2c).
The comet assay previously applied to HMA-treated
cells showed a net increase of single- and double-
strand breaks (SSBs and DSBs) [10]; here, we moni-
tored the γ-H2AX form of the H2AX histone that is
phosphorylated when DSBs are present in DNA [24].
In fact, as shown in Fig. 2d, a high fraction of HMA-
(See figure on previous page.)
Fig. 2 HMA stimulates ROS formation and mitochondrial membrane depolarization and affects DNA integrity. Effect of scavengers. a Quantification of
ROS by cytofluorimetric analysis of DCF (dichlorofluorescein) fluorescence in HCT-116 cells treated for increasing times (4 h to 24 h) with HMA (30 μM)
alone, or co-incubated with HMA and antioxidants (15 mM NAC or 400 μM α-Tocopherol, Toc) for the same time periods. b Measurement of
mitochondrial membrane potential by cytofluorimetric analysis of TMRM (tetramethylrodamine methylester) fluorescence in HCT-116 cells
treated as in (a). In a and b, data are expressed as fold increase with respect to untreated cells (mean ± s.d. calculated on three independent
experiments). *P < 0.05, **P < 0.01, ***P < 0.001. c Detection of DNA damage by 8-oxoguanine immunostaining of untreated and HMA (20 μM,
24 h)-treated HCT-116 cells; parallel samples were incubated simultaneously with HMA and with 15 mM NAC. d Detection of γ-H2AX by
immunostaining in untreated and HMA treated (20 μM, 24 h) HCT-116 cells. Scale bar: 50 μm. A representative experiment out of three is
shown in panels (c) and (d), where nuclei were counterstained with DAPI (blue fluorescence)
Fig. 3 Cell death induced by HMA. Involvement of RIPK3. a PI (Propidium Iodide) permeability of untreated and HMA-treated (10-40 μM, 24 h)
HCT-116 cells. Cytofluorimetric analysis allowed the quantification of PI+/dead cells detected on 10,000 events (mean ± s.d. calculated on three
independent experiments). **P < 0.01, ***P < 0.001. b Cytofluorimetric analysis of untreated and HCT-116 cells treated with HMA alone (30 μM and
40 μM) or together with 20 μM pancaspase inhibitor zVAD.fmk or necroptosis inhibitor Necrostatin-1 (NEC, 50 μM); parallel samples were
incubated with zVAD.fmk or NEC alone. Cells were stained with PI; values are expressed as percentage of PI positive events on 10,000
events recorded calculated on three independent experiments. *P < 0.05, ***P < 0.001, n.s. not significant. c Western blot analysis of necroptosis
proteins RIPK1, RIPK3 and MLKL in HT-29 cells untreated and treated with 30 μM HMA for 24 h. α-Tubulin: loading control. d Effect of silencing of RIPK3
by siRNA on HT-29 cell survival after a 30-μM HMA treatment (for 24 h). Cell death was monitored by flow cytometry after Annexin V/PI staining; four
fractions can be distinguished: PI+/A+: late apoptotic/necrotic cells; A+: early apoptotic cells; PI+: necrotic cells; unstained: alive cells. e Western
blot analysis of RIPK3 in HT-29 cells after transfection with siRNAs; γ-tubulin was used as loading control; red rectangle refers to the siRNA used
in d). A representative experiment out of three is shown in panels (c) and (e)
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treated cells (57.96 % ± 3.62), showed many red fluor-
escent nuclei (not visible in untreated cells), as expected
in γ-H2AX positive cells. Together, these data support the
notion that HMA was able to affect DNA integrity, pos-
sibly via ROS production.
RIPK3 contributes to HMA-induced cell death
The presence of DNA damage, a high amount of ROS
together with compromised mitochondria, as well as al-
terations in cell morphology after HMA treatment,
could have an impact on cell viability. We stained cells
with PI, which does not enter living cells, while it pene-
trates dying/dead cells, and analysed them by flow cy-
tometry. HCT-116 cells treated with increasing
concentrations of HMA (10-40 μM) for 24 h revealed a
highly significant (P < 0.001) dose-dependent increase in
the amount of PI+/dead cells, reaching about 50 % at
35 μM and remaining significant at 40 μM HMA (P <
0.001), even if the net number of PI+ cells declined to
about 40 % (Fig. 3a). No effect on cell viability was re-
corded in samples incubated with the drug solvent
DMSO (not shown).
How do HMA-treated cells die? We previously re-
ported that HMA was unable to trigger the final steps
of canonical apoptosis even if it promotes the activation
of the initiator caspase 8 and 9 [10]. However, given
that caspase 8 could be involved in a cross talk between
apoptosis and other forms of death [25], here we used
the pan-caspase inhibitor zVAD.fmk in combination
with HMA. Cells treated with 20 μM zVAD.fmk alone
showed a low amount of PI-permeable cells, similar to
untreated samples. PI-stained cells after a 24-h treat-
ment with 30 μM and 40 μM of HMA in the presence
of zVAD.fmk (20 μM) revealed a significant (P < 0.001)
decrease in the number of PI positive/dead cells com-
pared to HMA treatment alone (Fig. 3b), accounting
for 38.61 % ± 0.75 (30 μM HMA) and 25.42 % ± 4.16
after HMA/zVAD.fmk treatment. Analogously, for the
40 μM HMA concentration, the fraction of PI positive
cells decreased from 46.79 % ± 1.76 to 38.38 % ± 5.92,
highlighting a positive effect of the caspase inhibitor on
cell viability and suggesting that initiator caspase 8 and
9 could be involved in other subroutes of death driven
by HMA.
With this in mind, we investigated necroptosis, a death
process where a role for caspase 8 has been described
[26]. The possible involvement of necroptosis in the re-
sponse to HMA was first investigated in HCT-116 cells
by using the RIPK1 (receptor-interacting serine/threo-
nine-protein kinase1) inhibitor Necrostatin-1 (NEC,
50 μM), which did not affect cell viability per se (Fig. 3b).
When administered together with HMA (30 μM and
40 μM) for 24 h, NEC did not rescue HMA-induced cell
death (Fig. 3b), thus suggesting that in HCT-116 cells
RIPK1 is not involved in the cellular response to HMA,
as already shown in breast cancer cells [9]. To go dee-
per into the necroptosis issue by addressing the impact
of the other key regulator RIPK3, we used the HT-29
cell line, being HCT-116 cells characterised by a low
expression of RIPK3 [27].
Western blot analysis of the expression of necropto-
sis effectors RIPK1 and 3 and MLKL (mixed lineage
kinase domain-like) in untreated and HMA-treated
HT-29 samples. We observed a modulation in re-
sponse to the drug treatment, with an increase in
RIPK3 and MLKL proteins in HMA-treated samples
with respect to controls (1.60 and 1.97 fold, respect-
ively; P < 0.01) (Fig. 3c); however, in this cell line an
opposite trend was recorded for RIPK1 (0.60 fold de-
crease; P < 0.01). As reviewed by Lalaoui et al. [28],
the requirement of RIPK1 in necroptosis is not abso-
lute and cells lacking or expressing low levels of
RIPK1 (as it is the case of HT-29 cells) undergo
necroptosis by spontaneously increase the expression
levels of RIPK3 and MLKL, as here observed.
Focusing on RIPK3 in HT-29 cells, we then used a
different experimental approach, based on silencing
of RIPK3. In HT-29 cells silenced for RIPK3 expres-
sion (Fig. 3e), the cell population characterised not
only by PI permeability but also by late phosphatidyl-
serine expression detected with Annexin V was de-
creased upon treatment with HMA, leading to an
increase of the number of living cells from about
70 % to about 90 % (Fig. 3d). This suggests that the
kinase RIPK3 is required, at least in part, for cell
death induction by HMA.
Autophagy modulates cell response to HMA
We previously detected some autophagy markers in
HMA-treated colon carcinoma SW613-B3 cells [10], as
also confirmed in breast cancer cells [9]; now, we
addressed whether HMA drives a pro-survival or pro-
death role of autophagy. To do this, we silenced Atg7
and Beclin 1 autophagy effectors (Fig. 4b) and then we
analysed HCT-116 cell viability by Annexin V/PI stain-
ing. Both Atg7 and Beclin-1 silencing caused a decrease
in unstained/alive cells of about 40 % upon HMA-
treatment (from 79.03 % of control siRNA to 37.27 % for
Atg7 and 43.43 % for Beclin-1), as well as enhanced cell
death (Fig. 4a) supporting a protective role of autophagy
in the presence of HMA-induced stress. However,
autophagy was not completely efficient in rescuing cell
viability after HMA treatment.
To address this intriguing point, we investigated the
last events in the autophagy pathway. The final steps of
autophagy are characterised by the sequestration of fac-
tors to be discarded through the action of the protein
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p62, also called sequestosome, which drives the cargo
within autophagosomes, and is further degraded. In
HMA-treated cells, p62 was detected as several spots
(green fluorescence) and clustered both at nuclear and
cytoplasmic level independently of the drug concentra-
tion (20 μM or 40 μM) (Fig. 4c). In fact, the analysis of
Fig. 4 Activation of autophagy by HMA. Silencing of ATG7 and Beclin-1 by siRNA in HCT-116 cells. Impact of HMA on Ubiquitin and GRP78. a Effect of
silencing of ATG7 and Beclin-1 on HCT-116 cell survival after a 30-μM HMA treatment (for 24 h). Cell death was monitored by flow cytometry after
Annexin V/PI staining; four fractions can be distinguished: PI+/A+: late apoptotic/necrotic cells; A+: early apoptotic cells; PI+: necrotic cells; unstained:
alive cells. b Western blot analysis of Atg7 and Beclin-1 in HCT-116 cells after transfection with siRNAs; γ-tubulin: loading control. Red rectangles refer
to the siRNA used in a). c Immunofluorescence analysis of p62 (green fluorescence) in HCT-116 cells untreated and treated with 20 μM and 40 μM
HMA for 24 h. Nuclei were counterstained with DAPI (blue fluorescence). Scale bar: 50 μm. A representative experiment out of three is shown.
d Immunofluorescence analysis of Ubiquitin and GRP78 (red fluorescence) in HCT-116 cells untreated and treated with 20 μM HMA for 24 h; nuclei
were counterstained with DAPI (blue fluorescence)
Aredia et al. BMC Cancer  (2016) 16:851 Page 9 of 14
the global ubiquitination level using an antibody
against ubiquitin, revealed a low red fluorescent signal
in untreated samples, while in HMA-treated cells sev-
eral brilliant regions were visible (both in nuclear and
cytoplasmic regions), possibly coincident with p62 dis-
tribution (Fig. 4d). Moreover, we analysed the UPR
(unfolded protein response) marker GRP78 [29]: in
control cells, GRP78 staining appeared as a low diffuse
fluorescence, while in HMA-treated cells (20 μM) sev-
eral specific dots were visible, indicating that GRP78
protein remained accumulated after the drug insult
(Fig. 4d). Globally, our results point to a defect in the
last phase of autophagy, leading to an impaired clear-
ance of stress-damaged proteins and to an incomplete
protection against HMA-induced insults.
Poly(ADP-ribose) modulates HMA response
The evidence that HMA triggers DNA damage and
oxidative stress conditions prompted us to investigate
this effect on a cellular emergency reaction, i.e. poly(-
ADP-ribosylation), which we have already demon-
strated to be activated by HMA [8, 10]. We addressed
this issue in our experimental conditions by using the
PARP inhibitor Olaparib (OLAP) under conditions
abolishing PAR synthesis triggered by 20-μM HMA ex-
posure, that are 10 μM for 24 h (Fig. 5a). First, we
evaluated cell viability by the metabolic MTT assay,
observing once more the inhibitory effect of HMA
alone, causing a reduction of cell viability to 70.48 % ±
2.96 and, when combined to OLAP, decreasing to
50.24 % ± 4.74 (Fig. 5b), suggesting a net effect of the
PARP inhibitor, so a role of PAR in modulating cell re-
sponses to HMA-treatment. Is PAR pro-survival func-
tion connected to autophagy? To answer this question,
we monitored the autophagy marker LC3, generally
overexpressed in HMA-treated cells [9, 10]; in samples
co-treated with OLAP, a significant reduction of the
LC3 signal with respect to the HMA treatment alone
was observed (Fig. 5c), suggesting a possible require-
ment of PAR in the autophagy machinery [25, 30].
However, given the pleiotropic effects of PAR in cell
metabolism, further experiments are required to better
understand this issue.
Discussion
Among the approaches used to manipulate the regula-
tors of cancer cell homeostasis that favour proliferation
and spread, often correlated with the so called Warburg
Fig. 5 Effect of Olaparib on cell viability and autophagy. a Immunofluorescence detection of PAR (red) in HCT-116 cells treated for 24 h with
20 μM HMA without or with 10 μM Olaparib (OLAP). b MTT assay on samples as in (a) and in cells treated with OLAP only (10 μM for 24 h) or
untreated; ***P < 0.001. c Immunofluorescence analysis of autophagy marker LC3 expression (green fluorescence) in HCT-116 cells under the
above conditions; nuclei were counterstained with DAPI (blue fluorescence). Scale bar: 50 μm. A representative experiment out of three is shown
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effect [31], pH modulation through the targeting of the
plasma membrane effectors has been exploited. In this
context, amiloride, a clinically used potassium sparing
diuretic, and derivatives have been used to promote
intracytosolic acidification in cancer cells and ultimately
counteract their survival and proliferation [32]; however,
the mechanism of action leading to cancer cell death by
these compounds is far from being elucidated.
We investigated the properties of the amiloride deriva-
tive HMA (5-(N,N- hexamethylene) amiloride), which
was found to lower intracellular pH in rodent cells [33]
with the consequent activation of acid DNases causing
DNA degradation typical of caspase-independent par-
adigms of cell death [33]. In line with this pivotal
paper, we previously described a cytotoxic effect of
HMA on human Adult Retinal Pigmented Epithelium
19 (ARPE19) cells [8] and on a panel of human cancer
cell lines [10], where HMA did not trigger canonical
apoptosis but activated autophagy. In this respect, the
recent paper by Rowson-Hodel et al. [9] confirmed
that the cytotoxic effect of HMA on breast cancer cells
was not due to classical caspase-dependent apoptosis but
was triggered by a novel form of programmed necrosis.
In this study, we aimed to determine the molecular
events leading to colon cancer cell death, which may
happen through the destabilisation of organelles due to
the intracytosolic localisation of HMA once entered the
cell, as we have shown for the first time exploiting the
fluorescent properties of HMA [7] and confirmed here
by EM analysis (Fig. 1a). We focused on mitochondria,
which act as the control unit of the cell being involved
in the cell response to a wide range of insults [34], show-
ing that in HMA-treated colon cancer cells they ap-
peared to be relocalised to the perinuclear region (as
recently reported in breast cancer cells [9]) and func-
tionally impaired due to mitochondrial membrane
depolarization. This is in agreement with the observa-
tions obtained in erythroleukemia cells treated with 5-
(N-ethyl-N-isopropyl) amiloride [35] and in glioma
cells with 5-benzylglycinyl-amiloride [36] and with the
well-known inhibition of mitochondrial complex I ac-
tivity by amilorides [37].
Based on the connection between dynamic variations
in mitochondria, altered mitochondrial functions and
increased generation of mitochondrial ROS [38], we ob-
served a significant time-dependent increase in ROS,
partially rescued by NAC, which counteracted also mito-
chondrial membrane depolarization. Our data, in line
with the observation on breast cancer cells [9], raise an
unresolved debate: are mitochondria the primary/exclu-
sive source of ROS [39], or could ROS be originated
from other organelles in the cell (e.g. ER or peroxisomes)
and impact on mitochondria status/function? [40]. Re-
markably, in agreement with the notion that a high ROS
level can ultimately lead to DNA lesions [41], we found
that HMA induces an expected increase in both guanine
oxidation and histone H2AX phosphorylation. This first
set of data allowed the identification of the early molecu-
lar events triggered by HMA in colon cancer cells.
Which pathway(s) leading to cell death can be trig-
gered by mitochondrial structural/functional alter-
ations, DNA damage and ROS accumulation? Despite
the activation of initiator caspase 8 and 9, in our
experimental conditions the canonical apoptosis path-
way was not reaching the end, as both DNA ladder and
PARP-1 proteolysis were absent [10]; the absence of
PARP-1 proteolysis was recently described also in
HMA-treated breast cancer cells [9]. The inability to
end the apoptotic cascade is not intrinsic in colon can-
cer cells, having been reported that HCT-116 cells
undergo canonical apoptosis after various drug treat-
ments triggering ROS formation [42, 43]. However, the
impact of autophagy in driving cell response could ac-
count for this feature, as it occurs in our context and in
similar experimental conditions [44].
However, given that the pancaspase inhibitor zVAD.fmk
failed to provide complete protection against HMA, as also
reported in breast cancer cells [9], we considered
necroptosis, another subroutine of programmed cell
death [45, 46] that was recently shown to be triggered
by amiloride derivatives in breast cancer [11] and
glioma [12] cells. Although the inhibitor of RIPK1
Necrostatin-1 did not affect HMA cancer cell viability
in our experimental conditions and also in a similar
context [9], we found that the silencing of RIPK3
allowed a rescue in cell viability, indicating that this
necroptosis factor (and not RIPK1) could be involved in
cell death activation after HMA administration. The
impact of a necrosis-like death pathway has been de-
scribed in breast cancer cells [9], thus adding a new
entry in the complex scenario of HMA response by
cancer cells; this pathway was found to be independent
of RIPK3 and MLKL expression level [9], while our data
support their active role; these discrepant results can be
explained by the different biological material used. Fur-
ther investigations will clarify this issue.
To explore additional pathways leading to cell death
through DNA damage and oxidative stress conditions, we
focused on the accumulation of PAR (poly(ADP-ribose), a
signaling molecule for AIF (apoptosis inducing factor)
translocation from mitochondria that triggers nuclear
DNA degradation during PAR/AIF-dependent cell death
named parthanatos [47]. In fact, we previously demon-
strated the activation of this pathway in colon cancer cells
treated with HMA [10], and other groups confirmed our
findings in breast [11] and glioma [12] cancer cells treated
with 5-benzylglycinyl-amiloride and 5-glycinyl-amiloride.
The real impact of PAR-dependent processes on the
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survival of amiloride-treated cancer cells has been ad-
dressed previously using the 1st-generation PAR inhibitor
3-aminobenzamide, showing that the reduction in PAR
synthesis was ineffective in restoring cell viability [12].
However, here we used the last-generation compound
Olaparib under conditions leading to the complete inhib-
ition of PAR accumulation and we provide evidence that it
was able to enhance the loss of cell viability after the com-
bined administration with HMA.
Intriguingly, in HMA-treated cells we observed here
an unexpected effect of Olaparib on the expression of
the protein LC3, a marker of autophagy. The activation
of autophagy (often mediated by mitochondrial ROS
[48]) is necessary to degrade misfolded or damaged cell
components, including mitochondria, thus promoting
cancer cell survival. However, under extreme conditions,
it can act as programmed cell death mechanism type II
[49]. In our experimental conditions, autophagy played a
pro-survival role in cancer cells treated with HMA,
given that cell viability decreased, although only par-
tially, when the crucial autophagy regulators Beclin-1 or
ATG7 were silenced. Our data are in line with our previ-
ous evidence of a non-canonical form of HMA-driven
autophagy [10] and with the results provided by Leon et
al. [11] and Rowson-Hodel et al. [9] indicating that the
induction of autophagy cannot account for the majority
of HMA’s cytotoxic effects.
Why did autophagy fail in completely rescuing cancer
cells from the early effects of HMA? We hypothesize
that autophagosomes are unable to completely digest
their content, resulting in a deadlocking of the autoph-
agy machinery; in fact, electron microscopy images re-
vealed that multilamellar membranes, residual of
damaged organelles, are engulfed in membranes but not
completely degraded. Our hypothesis was confirmed by
the persistence of p62, ubiquitinated proteins and the
ER stress marker GRP78 in HMA-treated cells, which
are unable to efficiently discard the above proteins. Of
note, multilamellar bodies could originate from lyso-
somal organelles that are possibly involved in the
lysosome-dependent form of cell death recently identi-
fied in breast cancer cells treated with HMA [9].
Conclusions
In conclusion, as summarised in Fig. 6, we hypothesize
that HMA enters the cell, lowers intracytosolic pH, causes
Fig. 6 Multiple effects of HMA on colon cancer cell metabolism. HMA inhibits NHEs, thus lowering intracellular pH, enters the cell and induces
mechanical stress and metabolic perturbations, which, in turn, stimulate ROS production, causing damage to mitochondria and DNA. DNA
damage is then recognized by PARP-1 (poly(ADP-ribose) polymerase-1) that reacts to the dangerous situation by synthesizing high amounts of
PAR (poly(ADP-ribose). PAR can act here as a signalling death molecule for mitochondrial AIF (apoptosis inducing factor) , which is then released
from damaged mitochondria and, promotes cell death through the parthanatos process. After this cascade of events, autophagy is futile and its
stall contributes to cell death; moreover, a pathway of death dependent on the necroptosis factor RIPK3 becomes activated. In addition to these
factors/processes, other still unknown mechanisms (denoted as “???”) could be involved in HMA toxicity
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cytosol vacuolization and organelle destabilization, so de-
termining a mechanical stress, promotes ROS production
affecting mitochondrial functions and DNA integrity and
stimulates PAR synthesis, which triggers AIF-dependent
parthanatos death.
After this cascade of events, autophagy is futile and its
stall contributes to cell death; moreover, a pathway of
death dependent on the necroptosis factor RIPK3 be-
comes activated. Each factor/process here considered
could account only in part for HMA toxicity, thus other
mechanisms (denoted as “???”) must be involved in the
complex impact of HMA on cell survival, including lyso-
some and Ca2+-mediated death processes and impaired
cell survival axes [9]. The knowledge of the molecular
networks activated by HMA could be instrumental in
identifying key players in the attempt to improve the
global cancer cell response to HMA, possibly developing
a newly designed targeted therapy.
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